Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Research Article

L-Ala-L-Gln Suppresses Hypoxic Phenotype and Fibrogenic Activity of Rat Perineurial Fibroblasts

Author(s): Nilabh Ghosh, Catherine Bregere, Pia Bustos and Raphael Guzman*

Volume 22, Issue 5, 2023

Published on: 22 July, 2022

Page: [761 - 773] Pages: 13

DOI: 10.2174/1871527321666220414094149

open access plus

Abstract

Background: Twenty million Americans suffer from peripheral nerve injury (PNI) and approximately $150 billion is spent annually in the United States for the treatment of nerve injuries. Moreover, 50,000 cases of PNI repairs are performed annually in the United States, with even less than 42% experiencing satisfactory sensory recovery. Available therapies control painful symptoms but do not treat axonal degeneration or neuronal cell death. Peripheral nerve fibrosis (PNF) associated with chronic inflammation, perineural adhesions, and scarring is often reported in patients with nerve injury. Unfortunately, post-surgical adhesions and fibrosis often lead to aberrated wound healing and impairment of nerve functions. Various treatment strategies have been attempted, including the use of grafts and biomaterials; however, few appear promising.

Objective: L-Alanyl-L-Glutamine (L-Ala-L-Gln) was reported to protect the lung from sepsisinduced injury and play an immunomodulatory role in stress and fibrosis. This study aimed to examine the potential anti-fibrotic effects of L-Ala-L-Gln in an in vitro model of neural fibrosis.

Methods: Primary fibroblasts isolated from rat sciatic nerve were exposed to chronic (48 h) and episodic (2 h) hypoxic conditions. Cultures were then treated for 48 h with various concentrations of L-Ala-L-Gln (0, 1, 10, and 100 mM). The expression of hypoxic and pro-fibrotic markers in the different culture conditions was assessed by immunocytochemistry and western blot analyses. Quantitative phosphor-proteomic profiling was performed to investigate mechanistically the impact of L-Ala- L-Gln on collagen biosynthesis and hypoxia-driven tissue fibrosis in vitro.

Results: In protein expression assays, L-Ala-L-Gln significantly reduced markers related to the cellular response to hypoxia, in particular HIF-1 signaling. L-Ala-L-Gln also significantly reduced the expression of pro-fibrotic and cell-adhesion-inducing factors. Phospho-proteomic data indicated that L-Ala-L-Gln modulates several pro-fibrotic factors and associated pathways.

Conclusion: Altogether, our data demonstrate that L-Ala-L-Gln efficiently suppresses hypoxiamediated fibrotic processes at different concentrations in rat primary fibroblasts. Thus, L-Ala-L-Gln presents a high potential therapeutic value as an antifibrotic pharmaceutical agent for the treatment of neural fibrosis.

Keywords: Peripheral nerve fibrosis, peripheral nerve injury, hypoxia, HIF-1α, L-Ala-L-Gln, collagen, fibroblasts, extracellular matrix.

[1]
Khuong HT, Kumar R, Senjaya F, et al. Skin derived precursor Schwann cells improve behavioral recovery for acute and delayed nerve repair. Exp Neurol 2014; 254: 168-79.
[http://dx.doi.org/10.1016/j.expneurol.2014.01.002]
[2]
Goncalves NP, Teixeira-Coelho M, Saraiva MJ. The inflammatory response to sciatic nerve injury in a familial amyloidotic polyneuropathy mouse model. Exp Neurol 2014; 257: 76-87.
[http://dx.doi.org/10.1016/j.expneurol.2014.04.030]
[3]
Waller A. Experiments on the section of the glosso-pharyngeal and hypoglossal nerves of the frog, and observations of the alterations produced thereby in the structure of their primitive fibres. Edinb Med Surg J 1851; 76(189): 369-76.
[PMID: 30332247]
[4]
Brosius Lutz A, Barres BA. Contrasting the glial response to axon injury in the central and peripheral nervous systems. Dev Cell 2014; 28(1): 7-17.
[http://dx.doi.org/10.1016/j.devcel.2013.12.002] [PMID: 24434136]
[5]
Burnett MG, Zager EL. Pathophysiology of peripheral nerve injury: A brief review. Neurosurg Focus 2004; 16(5): E1.
[http://dx.doi.org/10.3171/foc.2004.16.5.2] [PMID: 15174821]
[6]
Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117(3): 524-9.
[http://dx.doi.org/10.1172/JCI31487] [PMID: 17332879]
[7]
Ghosh N, Kalbermatten D, Madduri S, Guzman R. Fibrosis and regulation of nerve regeneration in the peripheral and Central Nervous Systems. CNS Neurol Disord Drug Targets 2020; 19(8): 560-71.
[http://dx.doi.org/10.2174/1871527319666200726222558] [PMID: 32713338]
[8]
Penkert GFH. Anatomy and histological reaction of traumatized nerves. In: Peripheral Nerve Lesions. Berlin, Heidelberg: Springer 2004.
[http://dx.doi.org/10.1007/978-3-662-09232-3_2]
[9]
Dyck PJ, Lais AC, Karnes JL, et al. Permanent axotomy, a model of axonal atrophy and secondary segmental demyelination and remyelination. Ann Neurol 1981; 9(6): 575-83.
[http://dx.doi.org/10.1002/ana.410090611] [PMID: 7259120]
[10]
Jones KS. Effects of biomaterial-induced inflammation on fibrosis and rejection. Semin Immunol 2008; 20(2): 130-6.
[http://dx.doi.org/10.1016/j.smim.2007.11.005] [PMID: 18191409]
[11]
Xavier AM, Serafim KG, Higashi DT, et al. Simvastatin improves morphological and functional recovery of sciatic nerve injury in Wistar rats. Injury 2012; 43(3): 284-9.
[http://dx.doi.org/10.1016/j.injury.2011.05.036] [PMID: 21684542]
[12]
Kayacan O, Beder S, Deda G, Karnak D. Neurophysiological changes in COPD patients with chronic respiratory insufficiency. Acta Neurol Belg 2001; 101(3): 160-5.
[PMID: 11817264]
[13]
Hao JX, Blakeman KH, Yu W, Hultenby K, Xu XJ, Wiesenfeld-Hallin Z. Development of a mouse model of neuropathic pain following photochemically induced ischemia in the sciatic nerve. Exp Neurol 2000; 163(1): 231-8.
[http://dx.doi.org/10.1006/exnr.2000.7373] [PMID: 10785462]
[14]
Lim TK, Shi XQ, Johnson JM, et al. Peripheral nerve injury induces persistent vascular dysfunction and endoneurial hypoxia, contributing to the genesis of neuropathic pain. J Neurosci 2015; 35(8): 3346-59.
[http://dx.doi.org/10.1523/JNEUROSCI.4040-14.2015] [PMID: 25716835]
[15]
Imtiyaz HZ, Simon MC. Hypoxia-inducible factors as essential regulators of inflammation. Curr Top Microbiol Immunol 2010; 345: 105-20.
[http://dx.doi.org/10.1007/82_2010_74]
[16]
Semenza GL. Regulation of vascularization by hypoxia-inducible factor 1. Ann N Y Acad Sci 2009; 1177: 2-8.
[17]
Gilkes DM, Bajpai S, Chaturvedi P, Wirtz D, Semenza GL. Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J Biol Chem 2013; 288(15): 10819-29.
[http://dx.doi.org/10.1074/jbc.M112.442939] [PMID: 23423382]
[18]
Nayak BK, Shanmugasundaram K, Friedrichs WE, et al. HIF-1 Mediates renal fibrosis in OVE26 type 1 diabetic mice. Diabetes 2016; 65(5): 1387-97.
[http://dx.doi.org/10.2337/db15-0519] [PMID: 26908870]
[19]
Distler JH, Jüngel A, Pileckyte M, et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 2007; 56(12): 4203-15.
[http://dx.doi.org/10.1002/art.23074] [PMID: 18050252]
[20]
Stegen S, Laperre K, Eelen G, et al. HIF-1α metabolically controls collagen synthesis and modification in chondrocytes. Nature 2019; 565(7740): 511-5.
[http://dx.doi.org/10.1038/s41586-019-0874-3] [PMID: 30651640]
[21]
Zhang Q, Wu Y, Chau CH, Ann DK, Bertolami CN, Le AD. Crosstalk of hypoxia-mediated signaling pathways in upregulating plasminogen activator inhibitor-1 expression in keloid fibroblasts. J Cell Physiol 2004; 199(1): 89-97.
[http://dx.doi.org/10.1002/jcp.10452] [PMID: 14978738]
[22]
Mesarwi OA, Shin MK, Bevans-Fonti S, Schlesinger C, Shaw J, Polotsky VY. Hepatocyte hypoxia inducible factor-1 mediates the development of liver fibrosis in a mouse model of nonalcoholic fatty liver disease. PLoS One 2016; 11(12): e0168572.
[http://dx.doi.org/10.1371/journal.pone.0168572] [PMID: 28030556]
[23]
Goodwin J, Choi H, Hsieh MH, et al. Targeting hypoxia-inducible factor-1α/pyruvate dehydrogenase kinase 1 axis by dichloroacetate suppresses bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2018; 58(2): 216-31.
[http://dx.doi.org/10.1165/rcmb.2016-0186OC] [PMID: 28915065]
[24]
Cruzat V, Macedo Rogero M, Noel Keane K, Curi R, Newsholme P. Glutamine: Metabolism and immune function, supplementation and clinical translation. Nutrients 2018; 10(11): E1564.
[http://dx.doi.org/10.3390/nu10111564] [PMID: 30360490]
[25]
Wernerman J. Glutamine supplementation to critically ill patients? Crit Care 2014; 18(2): 214.
[http://dx.doi.org/10.1186/cc13781] [PMID: 25029635]
[26]
Fürst P. New developments in glutamine delivery. J Nutr 2001; 131(9) (Suppl.): 2562S-8S.
[http://dx.doi.org/10.1093/jn/131.9.2562S] [PMID: 11533314]
[27]
Déchelotte P, Hasselmann M, Cynober L, et al. L-alanyl-L-glutamine dipeptide-supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: The French controlled, randomized, double-blind, multicenter study. Crit Care Med 2006; 34(3): 598-604.
[http://dx.doi.org/10.1097/01.CCM.0000201004.30750.D1] [PMID: 16505644]
[28]
Fuentes-Orozco C, Cervantes-Guevara G, Muciño-Hernández I, et al. L-alanyl-L-glutamine-supplemented parenteral nutrition decreases infectious morbidity rate in patients with severe acute pancreatitis. J Parenter Enteral Nutr 2008; 32(4): 403-11.
[http://dx.doi.org/10.1177/0148607108319797] [PMID: 18596311]
[29]
Coëffier M, Miralles-Barrachina O, Le Pessot F, et al. Influence of glutamine on cytokine production by human gut in vitro. Cytokine 2001; 13(3): 148-54.
[http://dx.doi.org/10.1006/cyto.2000.0813] [PMID: 11161457]
[30]
Jewell JL, Kim YC, Russell RC, et al. Metabolism. Differential regulation of mTORC1 by leucine and glutamine. Science 2015; 347(6218): 194-8.
[http://dx.doi.org/10.1126/science.1259472] [PMID: 25567907]
[31]
Ferrantelli E, Liappas G, Vila Cuenca M, et al. The dipeptide alanyl-glutamine ameliorates peritoneal fibrosis and attenuates IL-17 dependent pathways during peritoneal dialysis. Kidney Int 2016; 89(3): 625-35.
[http://dx.doi.org/10.1016/j.kint.2015.12.005] [PMID: 26880457]
[32]
Ahrné E, Glatter T, Viganò C, Schubert C, Nigg EA, Schmidt A. Evaluation and improvement of quantification accuracy in isobaric mass tag-based protein quantification experiments. J Proteome Res 2016; 15(8): 2537-47.
[http://dx.doi.org/10.1021/acs.jproteome.6b00066] [PMID: 27345528]
[33]
Rockey DC, Bell PD, Hill JA. Fibrosis-a common pathway to organ injury and failure. N Engl J Med 2015; 372(12): 1138-49.
[http://dx.doi.org/10.1056/NEJMra1300575] [PMID: 25785971]
[34]
Dobaczewski M, Bujak M, Li N, et al. Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ Res 2010; 107(3): 418-28.
[http://dx.doi.org/10.1161/CIRCRESAHA.109.216101] [PMID: 20522804]
[35]
Mingyuan X, Qianqian P, Shengquan X, et al. Hypoxia-inducible factor-1α activates transforming growth factor-β1/Smad signaling and increases collagen deposition in dermal fibroblasts. Oncotarget 2017; 9(3): 3188-97.
[http://dx.doi.org/10.18632/oncotarget.23225] [PMID: 29423039]
[36]
Robertson LM, Fletcher NM, Diamond MP, Saed GM. Evitar (l-Alanyl-l-Glutamine) regulates key signaling molecules in the pathogenesis of postoperative tissue fibrosis. Reprod Sci 2019; 26(6): 724-33.
[http://dx.doi.org/10.1177/1933719118789511] [PMID: 30185141]
[37]
Déchelotte P, Darmaun D, Rongier M, Hecketsweiler B, Rigal O, Desjeux JF. Absorption and metabolic effects of enterally administered glutamine in humans. Am J Physiol 1991; 260(5 Pt 1): G677-82.
[PMID: 1903599]
[38]
Mittendorfer B, Gore DC, Herndon DN, Wolfe RR. Accelerated glutamine synthesis in critically ill patients cannot maintain normal intramuscular free glutamine concentration. JPEN J Parenter Enteral Nutr 1999; 23(5): 243-50.
[http://dx.doi.org/10.1177/0148607199023005243] [PMID: 10485436]
[39]
Aquino-Gálvez A, González-Ávila G, Jiménez-Sánchez LL, et al. Dysregulated expression of hypoxia-inducible factors augments myofibroblasts differentiation in idiopathic pulmonary fibrosis. Respir Res 2019; 20(1): 130.
[http://dx.doi.org/10.1186/s12931-019-1100-4] [PMID: 31234835]
[40]
Lagares D, Busnadiego O, García-Fernández RA, et al. Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation. Arthritis Rheum 2012; 64(5): 1653-64.
[http://dx.doi.org/10.1002/art.33482] [PMID: 22492165]
[41]
Li HY, Zhang QG, Chen JW, Chen SQ, Chen SY. The fibrotic role of phosphatidylinositol-3-kinase/Akt pathway in injured skeletal muscle after acute contusion. Int J Sports Med 2013; 34(9): 789-94.
[http://dx.doi.org/10.1055/s-0032-1333284] [PMID: 23444088]
[42]
Herrera J, Henke CA, Bitterman PB. Extracellular matrix as a driver of progressive fibrosis. J Clin Invest 2018; 128(1): 45-53.
[http://dx.doi.org/10.1172/JCI93557] [PMID: 29293088]
[43]
Martínez-Moreno CG, Calderón-Vallejo D, Harvey S, Arámburo C, Quintanar JL. Growth Hormone (GH) and Gonadotropin-Releasing Hormone (GnRH) in the central nervous system: A potential neurological combinatory therapy? Int J Mol Sci 2018; 19(2): E375.
[http://dx.doi.org/10.3390/ijms19020375] [PMID: 29373545]
[44]
Boots CV, Agnes W, Michael K, et al. Anti-fibrotic drugs differently affect inflammatory and redox status in bronchial epithelial cells from idiopathic pulmonary fibrosis patients. Eur Resp J 2019; 54: PA592.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy